AMPER Proof of Concept Study
Launched by UNIVERSITY OF STRATHCLYDE · Mar 19, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Diagnosis of probable Alzheimer's disease of mild to moderate severity according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and NINCS-ADRAD (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) criteria.
- • Age 50 or older
- • Sensory (visual and auditory), language, and physical abilities adequate to perform assessments (corrective aids allowed).
- • ACE III score between 20 and 82 (inclusive) (or equivalent score on MMSE (between 14 and 24, based on Law et al., 20123 equivalence data) or MOCHA (between 14 and 24 (based on Pendleberry et al., 2011 equivalence data).
- • Having a caregiver or family member who can attend all visits, perform assessments, and supervise administration of study.
- Exclusion Criteria:
- • Medical records indicate AD patients with the visual variant or having colour vision deficits.
- • Medical records indicate a CT or MRI within 24 months prior to screening that indicates a diagnosis other than probable Alzheimer's disease.
- • Medical records indicate any significant neurological disease other than probable AD (e.g. Parkinson's disease, Huntington's disease, brain tumor, normal pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of stroke, or history of head injury requiring hospitalization).
- • On review of medical records, no clinically significant abnormal findings on previous physical examination, medical history, or clinical laboratory results that would indicate an alternative diagnosis.
- • Current history of major psychiatric disorder (e.g. Major depression) (as indicated on medical records)
- • History of substance misuse (as indicated on medical records).
About University Of Strathclyde
The University of Strathclyde is a leading research institution based in Glasgow, Scotland, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, the university leverages its robust academic resources and interdisciplinary expertise to drive impactful research initiatives. With a focus on improving patient outcomes and fostering collaboration between academia and industry, the University of Strathclyde is dedicated to conducting high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately contributing to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported